Fisher & Paykel Healthcare Poised for Further Revenue Growth, Operating Leverage Over Next Few Years, RBC Says

MT Newswires Live09-16 13:27

Fisher & Paykel Healthcare (ASX:FPH, NZE:FPH) has a substantial growth opportunity in the hospital market given its dominant market position despite overall low market penetration, RBC Capital Markets said in a Tuesday note.

The company has delivered double-digit revenue growth over the past few years, supported by its high flow therapy devices in the hospital market and strong homecare growth due to mask launches.

RBC believes Fisher & Paykel can continue to achieve mid-to-high teens revenue growth and further operating leverage over the next few years despite an expected slowdown in homecare revenue growth in fiscal 2027.

Although the company trades at a significant valuation premium to peers, it has the lowest price/earnings-to-growth ratio among large-cap growth healthcare companies, RBC said.

It added that the strength of Fisher & Paykel's business could allow it to beat the top end of fiscal 2027 guidance for net profit after tax of NZ$525 million to NZ$565 million.

RBC upgraded its rating on the company to outperform and raised the price target to NZ$52 per share from NZ$39.

Fisher & Paykel Healthcare's New Zealand shares rose 2% at Wednesday's close, while its Australian shares gained 1% in recent trade.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2667727356?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-09-16 13:27","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2667727356","market":"fut","top_or_hot":-1,"title":"Fisher & Paykel Healthcare Poised for Further Revenue Growth, Operating Leverage Over Next Few Years, RBC Says","media":"MT Newswires Live","content":"<html><body><p> Fisher &amp; Paykel Healthcare (ASX:FPH, NZE:FPH) has a substantial growth opportunity in the hospital market given its dominant market position despite overall low market penetration, RBC Capital Markets said in a Tuesday note.</p><p>The company has delivered double-digit revenue growth over the past few years, supported by its high flow therapy devices in the hospital market and strong homecare growth due to mask launches.</p><p>RBC believes Fisher &amp; Paykel can continue to achieve mid-to-high teens revenue growth and further operating leverage over the next few years despite an expected slowdown in homecare revenue growth in fiscal 2027.</p><p>Although the company trades at a significant valuation premium to peers, it has the lowest price/earnings-to-growth ratio among large-cap growth healthcare companies, RBC said.</p><p>It added that the strength of Fisher &amp; Paykel's business could allow it to beat the top end of fiscal 2027 guidance for net profit after tax of NZ$525 million to NZ$565 million.</p><p>RBC upgraded its rating on the company to outperform and raised the price target to NZ$52 per share from NZ$39.</p><p>Fisher &amp; Paykel Healthcare's New Zealand shares rose 2% at Wednesday's close, while its Australian shares gained 1% in recent trade.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Fisher & Paykel Healthcare Poised for Further Revenue Growth, Operating Leverage Over Next Few Years, RBC Says</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nFisher & Paykel Healthcare Poised for Further Revenue Growth, Operating Leverage Over Next Few Years, RBC Says\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-09-16 13:27</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Fisher &amp; Paykel Healthcare (ASX:FPH, NZE:FPH) has a substantial growth opportunity in the hospital market given its dominant market position despite overall low market penetration, RBC Capital Markets said in a Tuesday note.</p><p>The company has delivered double-digit revenue growth over the past few years, supported by its high flow therapy devices in the hospital market and strong homecare growth due to mask launches.</p><p>RBC believes Fisher &amp; Paykel can continue to achieve mid-to-high teens revenue growth and further operating leverage over the next few years despite an expected slowdown in homecare revenue growth in fiscal 2027.</p><p>Although the company trades at a significant valuation premium to peers, it has the lowest price/earnings-to-growth ratio among large-cap growth healthcare companies, RBC said.</p><p>It added that the strength of Fisher &amp; Paykel's business could allow it to beat the top end of fiscal 2027 guidance for net profit after tax of NZ$525 million to NZ$565 million.</p><p>RBC upgraded its rating on the company to outperform and raised the price target to NZ$52 per share from NZ$39.</p><p>Fisher &amp; Paykel Healthcare's New Zealand shares rose 2% at Wednesday's close, while its Australian shares gained 1% in recent trade.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"XLV","symbol_name":"健康照护类股ETF-SPDR","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2667727356","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2667727356","pubTimestamp":1789536438,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Fisher & Paykel Healthcare  has a substantial growth opportunity in the hospital market given its dominant market position despite overall low market penetration, RBC Capital Markets said in a Tuesday note.The company has delivered double-digit revenue growth over the past few years, supported by its high flow therapy devices in the hospital market and strong homecare growth due to mask launches.RBC believes Fisher & Paykel can continue to achieve mid-to-high teens revenue growth and further operating leverage over the next few years despite an expected slowdown in homecare revenue growth in fiscal 2027.Although the company trades at a significant valuation premium to peers, it has the lowest price/earnings-to-growth ratio among large-cap growth healthcare companies, RBC said.It added that the strength of Fisher & Paykel's business could allow it to beat the top end of fiscal 2027 guidance for net profit after tax of NZ$525 million to NZ$565 million.RBC upgraded its rating on the compa","collect":0,"end_time":0,"defaultTopTitle":"","property":["rate","earning"],"viewcount":null,"language":"en","relate_stocks":{"XLV":"健康照护类股ETF-SPDR","FPH.NZ":"Fisher & Paykel Healthcare Corporation Limited Ord Shares"},"translate_title":"加拿大皇家银行表示，斐雪派克医疗保健公司有望在未来几年进一步增加收入和运营杠杆","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"FPH.NZ":1.5,"XLV":1.5},"content_text":"Fisher & Paykel Healthcare (ASX:FPH, NZE:FPH) has a substantial growth opportunity in the hospital market given its dominant market position despite overall low market penetration, RBC Capital Markets said in a Tuesday note.The company has delivered double-digit revenue growth over the past few years, supported by its high flow therapy devices in the hospital market and strong homecare growth due to mask launches.RBC believes Fisher & Paykel can continue to achieve mid-to-high teens revenue growth and further operating leverage over the next few years despite an expected slowdown in homecare revenue growth in fiscal 2027.Although the company trades at a significant valuation premium to peers, it has the lowest price/earnings-to-growth ratio among large-cap growth healthcare companies, RBC said.It added that the strength of Fisher & Paykel's business could allow it to beat the top end of fiscal 2027 guidance for net profit after tax of NZ$525 million to NZ$565 million.RBC upgraded its rating on the company to outperform and raised the price target to NZ$52 per share from NZ$39.Fisher & Paykel Healthcare's New Zealand shares rose 2% at Wednesday's close, while its Australian shares gained 1% in recent trade.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.50.0","shortVersion":"4.50.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2667727356","isCrawlerRequest":true}